分组1 - West Pharmaceutical Services reported quarterly earnings of $1.84 per share, exceeding the Zacks Consensus Estimate of $1.51 per share, and showing an increase from $1.52 per share a year ago, resulting in an earnings surprise of +21.85% [1] - The company achieved revenues of $766.5 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.39%, compared to $702.1 million in the same quarter last year [2] - West Pharmaceutical has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has underperformed the market, losing approximately 30.6% since the beginning of the year, while the S&P 500 has gained 8.1% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $1.62 on revenues of $761.41 million, and for the current fiscal year, it is $6.29 on revenues of $2.97 billion [7] 分组3 - The Medical - Dental Supplies industry, to which West Pharmaceutical belongs, is currently ranked in the top 21% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for West Pharmaceutical was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]